Andrew H. Wei

Andrew H. Wei, MBBS, PhD, FRACP, FRCPA is Professor and Head of the Blood Cancer Therapeutics Laboratory at the Australian Centre for Blood Diseases, Monash University, and a Consultant Haematologist in Melbourne. He is one of the world's leading experts on BCL-2-mediated apoptosis in AML and the clinical development of venetoclax-based combinations. Prof. Wei was the lead author of the pivotal Lancet 2020 paper reporting the results of the M14-358 phase Ib/II trial (later extended cohort) of venetoclax plus azacitidine in treatment-naive AML patients ineligible for intensive chemotherapy, demonstrating an unprecedented composite complete remission rate of 67% and median OS of 17.5 months — results that directly supported the FDA and EMA approvals of this combination and were foundational to the VIALE-A phase III trial. His laboratory has made foundational contributions to understanding BCL-2 family member dependencies in AML subsets, identifying that IDH-mutated and NPM1-mutated AML have heightened BCL-2 dependence while TP53-mutated AML relies more on MCL-1 — insights that drive biomarker-driven venetoclax combination design. Prof. Wei pioneered BH3 profiling as a functional assay to measure mitochondrial priming and predict venetoclax sensitivity, and has extensively characterized mechanisms of acquired venetoclax resistance including MCL-1 upregulation, FLT3 activation, and metabolic adaptation. He has authored over 150 peer-reviewed publications and is a principal investigator in numerous international AML trials.